- Home
- ARMN vs NRIX Comparison
ARMN vs NRIX Comparison
Compare ARMN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- NRIX
- Stock Information
- Founded
- ARMN 1992
- NRIX 2009
- Country
- ARMN Canada
- NRIX United States
- Employees
- ARMN N/A
- NRIX N/A
- Industry
- ARMN
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- NRIX Health Care
- Exchange
- ARMN Nasdaq
- NRIX Nasdaq
- Market Cap
- ARMN 2.0B
- NRIX 1.7B
- IPO Year
- ARMN N/A
- NRIX 2020
- Fundamental
- Price
- ARMN $13.99
- NRIX $17.21
- Analyst Decision
- ARMN Strong Buy
- NRIX Strong Buy
- Analyst Count
- ARMN 1
- NRIX 14
- Target Price
- ARMN $17.00
- NRIX $26.50
- AVG Volume (30 Days)
- ARMN 1.4M
- NRIX 1.6M
- Earning Date
- ARMN 10-29-2025
- NRIX 10-09-2025
- Dividend Yield
- ARMN N/A
- NRIX N/A
- EPS Growth
- ARMN N/A
- NRIX N/A
- EPS
- ARMN 0.26
- NRIX N/A
- Revenue
- ARMN $770,175,000.00
- NRIX $83,687,000.00
- Revenue This Year
- ARMN $82.77
- NRIX $58.48
- Revenue Next Year
- ARMN $73.80
- NRIX N/A
- P/E Ratio
- ARMN $57.70
- NRIX N/A
- Revenue Growth
- ARMN 58.96
- NRIX 48.32
- 52 Week Low
- ARMN $3.29
- NRIX $8.18
- 52 Week High
- ARMN $14.03
- NRIX $23.00
- Technical
- Relative Strength Index (RSI)
- ARMN 77.77
- NRIX 79.85
- Support Level
- ARMN $11.25
- NRIX $16.63
- Resistance Level
- ARMN $12.17
- NRIX $17.65
- Average True Range (ATR)
- ARMN 0.60
- NRIX 1.00
- MACD
- ARMN 0.28
- NRIX 0.42
- Stochastic Oscillator
- ARMN 99.66
- NRIX 92.98
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.